Drugs / Zopapogene imadenovec
Zopapogene imadenovec
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT06538480 | Jul 2024 → Dec 2027 expected | human papilloma virus infection, recurrent respiratory papillomatosis | Precigen, Inc | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Zopapogene imadenovec | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06538480 ↗ |
| Known as | Zopa | “Zopapogene imadenovec (Zopa)” NCT06538480 ↗ |
| Known as | Zopapogen imadenovec | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068194 ↗ |
| Route | Subcutaneous | “subcutaneous administrations” NCT06538480 ↗ |